Is Becoming France the Answer to Medicare's Biggest Problem?

France has found an interesting way to save money on health care expenses. Read below for more.

Jul 13, 2014 at 1:35PM

News from France was a bit mixed for Roche (NASDAQOTH:RHHBY) this week, with lawmakers voting to allow use of Roche's cancer drug Avastin as a cheaper alternative for eye treatment drug Lucentis, which is marketed by Novartis (NYSE:NVS) and...Roche (how awkward). Although Avastin is a cancer drug and not indicated for age-related macular degeneration (AMD), which Lucentis is indicated for, lawmakers want to encourage doctors to prescribe Avastin off-label for the eye condition as the drugs work in a similar fashion.

Now, how much money are we talking about saving in France? About $273 million -- really not that much considering that Lucentis revenue for Novartis (which markets the drug outside the U.S.) was $2.4 billion. But in price-conscious Europe, the concern is that more countries could do something similar, potentially harming revenue in one of the world's largest drug markets. Other countries in Europe are already taking their own action -- Italy, for example, has sought $1.6 billion in damages relating to an alleged collusion between Novartis and Roche to prevent Avastin from being used as an AMD therapy.

That's nice, but what does this have to do with Medicare?
A study in Health Affairs indicates that switching patients from Lucentis to Avastin would save Medicare $3 billion. That's a nice chunk of change, and with the federal government and insurers struggling to bend the cost curve and contain health care spending, it could be an intriguing opportunity for Medicare to copy France and save a bundle of money.

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson discuss this cost-savings fight and what it could mean for Roche, Novartis, and their competitors.

Cost-savings is yesterday's news. This could be tomorrow's.
We've all read the headlines about governments seeking to bend the cost curve and save money -- we already know about the stocks that will benefit from that, so it's already priced in. But the best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

David Williamson owns shares of Novartis. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers